Esperion Therapeutics, Inc. (ESPR) Stock Price

ESPRStock

$0.00−81.48%52W

Market Cap—

P/E—

PEG Ratio—

Div yield—

Beta0.49

ESPR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-24.79%

Price vs S&P 500 (4W)-1.38%

VGM Score59.06

Book Value / Share (Quarterly)$0.32

P/TBV (Annual)82.30x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)74.78%

Cash Flow / Share (Quarterly)$-0.07

Price vs S&P 500 (YTD)-24.76%

Gross Margin (TTM)68.38%

Net Profit Margin (TTM)-1.77%

EPS (TTM)$-0.06

10-Day Avg Trading Volume21.88M

EPS Excl Extra (TTM)$-0.06

Revenue Growth (5Y)12.12%

EPS (Annual)$-0.11

ROI (Annual)-486.00%

Gross Margin (Annual)67.95%

Net Profit Margin (5Y Avg)-170.77%

Cash / Share (Quarterly)$0.61

Revenue Growth QoQ (YoY)23.25%

ROA (Last FY)-4.87%

Revenue Growth TTM (YoY)61.13%

EBITD / Share (TTM)$0.34

ROE (5Y Avg)-171.90%

Operating Margin (TTM)18.12%

Cash Flow / Share (Annual)$-0.05

P/B Ratio91.05x

P/B Ratio (Quarterly)114.92x

Net Income / Employee (Annual)$-77,100

EV / Revenue (TTM)2.88x

Net Interest Coverage (TTM)0.74x

ROA (TTM)-1.81%

EV / EBITDA (TTM)15.87x

EPS Incl Extra (Annual)$-0.11

Current Ratio (Annual)1.54x

Quick Ratio (Quarterly)0.96x

3-Month Avg Trading Volume12.63M

52-Week Price Return-81.48%

Revenue / Employee (TTM)$1,422,600

Tangible BV / Share (Quarterly)$0.32

P/S Ratio (Annual)2.03x

Asset Turnover (Annual)0.87x

52-Week High$4.18

Operating Margin (5Y Avg)-129.17%

EPS Excl Extra (Annual)$-0.11

CapEx CAGR (5Y)-19.71%

Tangible BV CAGR (5Y)-31.73%

26-Week Price Return-14.29%

Quick Ratio (Annual)1.02x

13-Week Price Return36.48%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.53x

Enterprise Value$1.20B

Revenue / Share Growth (5Y)-25.18%

Asset Turnover (TTM)1.02x

Book Value / Share Growth (5Y)-35.70%

Revenue / Employee (Annual)$1,371,200

Inventory Turnover (Annual)1.29x

Pretax Margin (Annual)-5.17%

Cash / Share (Annual)$0.68

3-Month Return Std Dev113.82%

Gross Margin (5Y Avg)71.25%

Net Income / Employee (TTM)$-25,200

ROE (Last FY)-486.00%

Net Interest Coverage (Annual)0.93x

EPS Basic Excl Extra (Annual)$-0.11

P/FCF (TTM)18.11x

Receivables Turnover (TTM)3.92x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.06

Receivables Turnover (Annual)3.66x

ROI (TTM)-59.48%

P/S Ratio (TTM)1.96x

Pretax Margin (5Y Avg)-170.68%

Revenue / Share (Annual)$1.94

Tangible BV / Share (Annual)$0.72

Forward P/E21.01x

Price vs S&P 500 (52W)-83.64%

Year-to-Date Return-14.05%

5-Day Price Return0.95%

EPS Normalized (Annual)$-0.11

ROA (5Y Avg)-57.28%

Net Profit Margin (Annual)-5.63%

Month-to-Date Return0.63%

Cash Flow / Share (TTM)$-2.23

EBITD / Share (Annual)$0.29

Operating Margin (Annual)14.95%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-171.72%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.06

P/TBV (Quarterly)116.21x

P/B Ratio (Annual)81.89x

Inventory Turnover (TTM)1.30x

Pretax Margin (TTM)-1.33%

Book Value / Share (Annual)$0.72

Price vs S&P 500 (13W)24.80%

Beta0.49x

Revenue / Share (TTM)$1.66

ROE (TTM)-59.48%

52-Week Low$1.80

vGradeC

gGradeB

mGradeB

vgmGradeC

ESPR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q1 2026	May 8, 2026	-$0.03	-$0.10	-233.33%(-$0.07)
Q4 2025	Mar 10, 2026	$0.28	$0.22	-22.54%(-$0.06)
Q3 2025	Nov 6, 2025	-$0.08	-$0.16	-103.64%(-$0.08)
Q2 2025	Aug 5, 2025	-$0.16	-$0.02	+87.50%(+$0.14)

ESPR Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

2.55

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ESPREsperion Therapeutics, Inc.	C	B	B	2.0x	61.1%	68.4%	—	$0.00
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Esperion Therapeutics, Inc.

Esperion Therapeutics develops and commercializes oral, once-daily non-statin therapies for patients with elevated LDL cholesterol. The company's portfolio includes NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI, providing accessible alternatives to traditional statins. Esperion focuses on addressing the significant patient population requiring innovative lipid management solutions.